BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
04 6월 2024 - 5:01AM
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a
commercial-stage biopharmaceutical company focused on genetic
diseases, today announced that members of its management team,
along with Ravi Savarirayan, M.D., Ph.D., of Murdoch Children’s
Research Institute in Melbourne, Australia, and the global lead
investigator for PROPEL 2, will host a call on June 4, 2024, at
8:00 am ET to share results from Month 12 and Month 18 from Cohort
5 of PROPEL 2, a Phase 2 trial of the investigational oral therapy
infigratinib in children with achondroplasia.
To access the live webcast, please visit the
“Events” page within the Investors section of the BridgeBio website
at http://investor.bridgebio.com. A replay of the
webcast will be available on the BridgeBio website for 90 days
following the event.
About BridgeBio Pharma, Inc.BridgeBio Pharma
(BridgeBio) is a commercial-stage biopharmaceutical company founded
to discover, create, test and deliver transformative medicines to
treat patients who suffer from genetic diseases. BridgeBio’s
pipeline of development programs ranges from early science to
advanced clinical trials. BridgeBio was founded in 2015 and its
team of experienced drug discoverers, developers and innovators are
committed to applying advances in genetic medicine to help patients
as quickly as possible. For more information
visit bridgebio.com and follow us
on LinkedIn and Twitter.
BridgeBio Contact:Vikram
Balicontact@bridgebio.com(650)-789-8220
BridgeBio Pharma (NASDAQ:BBIO)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
BridgeBio Pharma (NASDAQ:BBIO)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024